127 Septicaemia due to Ewingella americana in a cancer patient: A case report  by Georgala, A. et al.
$70 International Journal o[ In[ectious Diseases (2006) 10($1 ) Abstracts 
occurred 17.8 days after treatment. At[ but 1 
patient (93%) were neutropenic and neutropenia 
tasted 20.4 days before bacteremia. Twenty-six pa- 
tients (83.9%) had central venous catheters (CVC). 
At[ patients received antibiotics. Twenty-five pa- 
tients (80.6%) received carbapenems for a mean 
of 10.2 days (range 2-31 days) before onset of 
SM bacteremia. Almost at[ patients (93%) manifest 
infection with fever ranging from 37.6 to 40.2°C. 
Hypotension occurred in 5 patients (16.7%). Eigh- 
teen patients (58.1%) had symptoms related to: 
respiratory system (25.8%), skin (12.9%), CVC (6%) 
and gastrointestinal tract (16.1%); but SM was iso- 
lated only from the sputum of 4 patients and soft 
tissue of one. Complications were uncommon: 3 pa- 
tients (9.7%) had renal failure and 3 had respiratory 
compromise. The mean Apache-II score on day of 
bacteremia was 18.7. Twelve patients (38.7%) re- 
quired admission to ICU. CVC was removed in 13 pa- 
tients (41.9%). Twenty-four patients (77.4%) were 
treated with Bactrim and 2 (6.5%) had quino[ones. 
Five patients (16.1%) received inappropriate antibi- 
otics and at[ died. Mortality rate was 35.5% (11 
patients) but 3 deaths were deemed unrelated to 
SM infection. 
Conclusions: In hematology patients with pro- 
tonged hospitalization and neutropenia, SM bac- 
teremia should be considered when fever occurs 
despite broad-spectrum antibiotics. 
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Background: Therapy-related mye[osuppression is 
more common in older patients (pts) with DLBCL 
who are treated with regimens such as cyc[o- 
phosphamide, doxorubicin, vincMstine, prednisone 
(CHOP), with or without Mtuximab (R). FebM[e 
neutropenia (FN) may subsequently complicate the 
course of these patients. We examined the oc- 
currence of FN among a large series of older pts 
with DLBCL treated with either CHOP or R-CHOP 
on an onco[ogy intergroup tr ial  Risk factors for the 
occurrence of FN were identified among these pts. 
Objectives: To determine: (1) the incidence of FN 
in this pt population, and (2) risk factors that are 
predictive for the occurrence of FN in these pts. 
Methods: Pts >60 years of age with previously 
untreated DLBCL enrolled on a US onco[ogy coop- 
erative group trial (CALGB 9793/ECOG-SWOG 4494) 
were randomized to initial therapy with either 
(CHOP) or (R-CHOP). Data regarding the nadir neu- 
trophi[ counts and complications of FN were col- 
lected. The incidence of FN was ascertained, and 
baseline demographic features that were predic- 
tive for the occurrence of FN were identified. 
Results: Of the 632 pts enrolled on this trial, 
data was available for 520 pts with regard to 
nadir counts and the occurrence of FN. Among 
these 520 pts, 212 (41%) had at [east one episode 
of FN complicating their treatment course. Overall, 
FN occurred in 261/3216 cycles of therapy (8%). 
The median time to FN was Day 11, with 38% of 
at[ FN episodes occurring in cycle one of ther- 
apy. Of these 520 patients, 141 had at [east one 
hospitalization for FN, with a median period of 
hospitalization of five (range, 1-121) days. The 
occurrence of FN in cycle 1 of therapy was as- 
sessed by the study entry demographics, to identify 
risk factors for this complication. Analysis of only 
cycle 1 was undertaken in order to minimize the 
impact of dose reduction, dose delay, and mye[oid 
growth factor usage. Factors found to be predictive 
for cycle 1 FN included advancing age (evaluated as 
a continuous variable, p = 0.001), a tess favorable 
performance status (PS 2,3) (p=0.02), baseline 
hemoglobin of <12g/d[ (p= 0.0001), an elevated 
LDH (p=0.02), and a high-intermediate/high risk 
International Prognostic Index (IPI) score (p = 0.02). 
The presence of marrow involvement had no im- 
pact on the occurrence of FN. 
Conclusions: FN is a common occurrence among 
older pts with DLBCL receiving anthracyc[ine-based 
chemotherapy regimens. This complication tends 
to occur early in the treatment course. Risk fac- 
tors for the subsequent occurrence of FN include 
advancing age, poor PS, anemia, elevated LDH, and 
high-intermediate/high risk IPI score. Using these 
predictive factors, pt subgroups may be identified 
at baseline that wi[[ most benefit from mye[oid 
growth factor support with their therapy. 
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Introduction: Septicaemia due to unusual bacteria 
may be difficult to establish and often difficult to 
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treat. We describe a case of E. americana sep- 
ticaemia in a cancer patient successfuLLy treated 
with antibiotics. 
Case report: A sixty-five yr-otd BeLgian woman 
was hospitatised with a recent diagnosis of colon 
adenocarcinoma, massive hepatic metastases and 
right pleura[ effusion. She was referred to our 
institution one week after the diagnosis. Previ- 
ous medical history was unremarkabLe. The di- 
agnosis was made after development of tender- 
ness of right hypochondrium. On admission, the 
patient presented an important jaundice, a right 
pleura[ effusion and a flapping tremor. Two days 
after the admission, we decided to start quickly 
chemotherapy because of exponential alteration 
of Liver tests. Five days after the beginning of 
chemotherapy, she developed fever with chiLLs. 
There was no cLinicaL site of infection but angio- 
chotitis was suspected because of progressive aLter- 
ation of Liver enzymes. After microbioLogicaL doc- 
umentation (bLood, urine), we empiricaLLy started 
cefuroxime (1.5 g tid) and ornidazote (1 g a qd). She 
responded welt to antibiotics, became afebrite and 
decreased CRP and WBC count. Urine culture was 
negative but blood cultures yielded Gram-negative 
baciLLi which was identified as E. americana by the 
VITEK ® identification system. 
The antimicrobia[ susceptibility test carried out by 
disk diffusion method showed resistance against 
cefuroxime; curiously the patient became afebrite 
under cefuroxime/ornidazote. However, we shifted 
antibiotics to ciprofloxacin (500 mg bid) and main- 
tained ornidazote. An improvement of Liver tests 
was also observed, probably due to chemotherapy. 
Conclusion: E. americana is a Gram-negative baciL- 
Lus belonging to the family of Enterobacteriacae; 
the reservoir and the cLinicaL significance of this 
germ are not precisely established. E. americana 
infection in immunocompromised patients uch as 
cancer patients is uncommon; to our knowledge 
this is the first case of septicaemia in a cancer pa- 
tient undergoing chemotherapy. 
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Background: Invasive mould infections (IMI) are 
a major cause of morbidity and mortality among 
patients with hematoLogicaL malignancies. Differ- 
ent institutions have different epidemioLogy of IMI. 
Hospital air can be a reservoir for moulds. In our 
institution, Aspergillus spp. are the most frequent 
cause of IMI foLLowed by Alternaria spp. 
Objectives: We conducted a one-year prospective 
study to evaluate the epidemioLogy of moulds in 
our hospital air. 
Methods: The air of 44 indoor (16 rooms [4 waLL- 
HEM, 6 portable HEPA], 13 bathrooms, 15 common 
areas) and 5 outdoor areas were tested 3 times 
a day (morning, noon, afternoon) once a month, 
four months a year (spring 2004, summer, faLL, 
and winter 2005) using a portable volumetric air 
sampler (SAS SUPER 90, pbi InternationaL, MiLano, 
ItaLy). MaLt extract agar added with cLoramphenico[ 
(250mg/[) was used as medium culture. PLates 
were incubated for 3-5 days at 25°C. CoLony counts 
were done by conventional methods. MouLds iden- 
tification was made by culturing them on potato 
dextrose agar. CoLony counts were enumerated as 
coLony-forming units per m 3 of air (CFU/m3). 
Results: 660 indoor and 75 outdoor air samples 
were obtained. The airborne concentrations of 
moulds are shown in the table. 
Area (n samples) Airborne concentrations of moutds, median (range) 
Spring Summer FaLL Winter Spring 
2004 2005 2005 2005 2005 
November February May August November 
Rooms (240) 78 263 167 81 91 
(5-267) (5-827) (0-352) (0-390) (0-388) 
Bathrooms (195) 35 167 122 30 38 
(3-283) (37-368) (0-328) (3-107) (0-230) 
Common areas (225) 103 250 160 132 75 
(8-450) (30-928) (50-262) (18-262) (53-172) 
Outdoor air (75) 272 587 348 213 677 









(+) Indoor areas (44 areas, 528 samples) (+) Outdoor air (5 areas, 60 samples) 
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Distribution of airborne mou[ds (4 sampUngs, 1 per season) 
The distribution of genera is shown in the figure. 
The most frequent opportunistic fungi found in 
indoor and outdoor air were Aspergillus spp. fob 
towed by Alternaria and Fusarium spp. 
Conclusions: We found a high toad of moulds in 
hospital air with a median that ranged from 78 to 
263 CFU/m 3. The highest counts were observed in 
summer. The most prevalent genera in indoor air 
were Aspergillus foLLowed by Alternaria and Fusar- 
ium spp. This distribution of genera matches our 
Local epidemioLogy of IMI. 
